参与者/女性 |
30/20 |
年龄 |
60±15 |
pulmonary hypertension classification |
|
Pulmonary arterial hypertension |
14 (47) |
Idiopathic |
12(40) |
Connective tissue disease-related |
2(7) |
CTEPH |
16 (53) |
Right heart catheter data and systemic blood pressure |
|
Mean pulmonary artery pressure mmHg |
39±11 |
Pulmonary artery wedge pressure mmHg |
11±3 |
Right atrial pressure mmHg |
8±4 |
Cardiac index L·min-1·m-2 |
3.0±0.8 |
Pulmonary vascular resistance Wood units |
5.8±3.0 |
Mixed venous oxygen saturation % |
67±8 |
Heart rate beats·min-1 |
70±12 |
Systemic blood pressure, systolic mmHg |
126±18 |
Systemic blood pressure, diastolic mmHg |
75±13 |
Arterial blood gas analysis |
|
pH |
7.42±0.04 |
pAO2kPa |
10.0±1.7 |
pACO2kPa |
4.5±0.5 |
肺功能 |
|
FEV1%pred |
88±22 |
FVC % pred |
93±22 |
FEV1/FVC % |
77±8 |
dLCO%pred |
69±15 |
pulmonary hypertension treatment |
|
土耳其内皮素tor antagonist |
19(63) |
Phosphodiesterase-5 inhibtor |
14 (47) |
Soluble guanylate cyclase stimulator |
8(28) |
Prostanoids |
3(10) |
Combination therapy |
11(37) |